Combination treatment with BRAF (vemurafenib, dabrafenib or encorafenib) and downstream MEK (trametinib or binimetinib) inhibitors is recommended for patients with advanced BRAF-mutant melanoma [5–7]. The gene discussed is MAP2K7; the disease is melanoma.